Retatrutide
Status: Investigational; not FDA approved
Receptor target: GIP, GLP-1, and glucagon receptor agonist
Availability: Lilly clinical trials only while investigational
Do not treat online listings as approved access.
Comparison
GLP treatment comparison tool
Use this as a status map, not as treatment selection. Suitability and prescribing decisions require a qualified clinician.
Compare status and mechanism
Tirzepatide
Status: FDA-approved products exist for specific labeled uses
Receptor target: GIP and GLP-1 receptor agonist
Availability: Prescription product through regulated channels when clinically appropriate
Not equivalent to retatrutide and not a conversion chart.
Medical disclaimer
This tool is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Retatrutide is investigational and is not FDA approved.